Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — IPO Roadshow (May 2020)
26 slides from Inspiremd's IPO roadshow presentation, May 26, 2020
Slide 1: Issuer Free Writing Prospectus - InspireMD
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 26, 2020 Relating to Prospectus filed May, 26, 2020 Registration Statement No. 333- 238247 inspireliiD This presentation highlights basic information about InspireMD, Inc. and the offering. InspireMD, Inc. has filed a registration s
Slide 2: Issuer Free Writing Prospectus Filed Pursuant to Rule 433
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Registration Statement No. 333-238247 4 A 2 stained Embolic Protection This presentation shall there be any sale of secu laws of any such jurisdi inspireMD
Slide 3: Disclaimers
Disclaimers This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," “anticipates,” "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements ar
Slide 4: Offering Summary
m™ Offering Summary Exchange: Ticker NYSE American: NSPR Offering Size Up to $10 million Over Allotment 15% Offering Details Common Stock and/or Prefunded Warrants Use of Proceeds We plan to use the net proceeds of this offering for research and development, sales and marketing, and working capital
Slide 5: About InspireMD
M™ About InspireMD InspireMD Is a commercial-stage medical device company focused on stroke prevention in patients with carotid artery disease and treatment of other minimally Invasive indications utilizing an integrated thin, 20-micron polyethylene terephthalate mesh MicroNet™ is a proprietary plat
Slide 6: Our Leadership
M™ Our Leadership Marvin L. Slosman President and CEO Craig Shore CFO Paul Stuka Chairman Michael Berman Director Campbell Rogers, M.D. Director Thomas Kester Director Mr. Slosman has over 30 years of experience in the medical device industry with focused leadership in commercialization and internat
Slide 7: InspireMD Pipeline
InspireMD Pipeline Peripheral Treatment: g Neuro Treatment: References: 1. Musialek P et al. PARADIGM-Extend Prospective Acaclemic Trial: Accumulating long-term evidence for MicroNet-covered stent safety and stroke prevention efficacy. Presentation at ESC Congress 2019, Paris, France, 31 August 2019
Slide 8: Endovascular Procedures: Landscape and InspireMD Potential
Endovascular Procedures: Landscape and InspireMD Potential CAROTID ARTERY DISEASE 20% Endo® , 80% Surgical® STILL AWAITING CONVERSION Already have been converted to endovascular procedures Guez, D,, Hansberry, D.R., Gonsalves, C.F, Eschelman, DJ, Parker, L, Rao, V.M., & Levin, D.C. Recent Trends in
Slide 9: Stroke is the Second Biggest Cause of Death Globally
Mi Stroke is the Second Biggest Cause of Death Globally An estimated 15 million people suffer from stroke annually’ * 6.2 million deaths? *5 million people left permanently disabled! * $34 billion associated with stroke management in the US alone? *~85% of all strokes are ischemic strokes, which res
Slide 10: The Problem: Risks with Existing Approaches to CAD
mi THE PROBLEM: Risks with Existing Approaches to CAD Surgery (CEA) and conventional Carotid Artery Stenting (CAS) both come with risks Carotid Endarterectomy (CEA) Carotid Artery Stenting (CAS) Risk of complications: Risk of complications: * Myocardial infarction risk? (heart attack) * Procedural a
Slide 11: The Problem: Risk of Embolism Following Conventional CAS
THE PROBLEM: Risk of Embolism Following Conventional CAS hater St 90% occlusion of MRI of a pre-existing white Successful MRI reveals new multiple micro- the carotid matter infarction opening of the infarcts (obstructions) due to artery (obstruction) carotid artery liberation of embolic particles
Slide 12: Our Solution: Proprietary MicroNet Technology
Mi OUR SOLUTION: Proprietary MicroNet™ Technology New mesh covered stent that offers superior plaque coverage when compared to conventional stent approaches Conventional Stent: Bare or dual layer approach, with plaque protrusion risk Protrading plaquetthrombus Detween struts Image: Prof. Valdés Chav
Slide 13: Carotid Solution: Our Well Studied Mesh-Covered Technology
M™ Carotid Solution: Our Well Studied Mesh-Covered Technology More than 1,500 patients in Clinical Publications and Studies {nikal Clinical Resules and In Vitro Testing of the New CGuard MicroNet-Covered “One-Sise-Fit-ll" Carotid Stent Ste om inspireMD éontdentat (3
Slide 14: Timeline Growth: From Alternative Stent to New Gold Standard
imeline Growth: From Alternative Stent to New Gold Standard YEAR STUDY PUBLICATION HIGHLIGHTS CGUARD™’S STANDING (known & antici a Large long-term study for all commers; CGuard™ study of long-term results O) cGuard™ demonstrates OPTIMA * IVUS assessment after CGuard™; intended to demonstrate plaque
Slide 15: CGuard EPS Yields Superior Clinical Outcomes
M™ CGuard™ EPS Yields Superior Clinical Outcomes When compared with Conventional Stents and Surgery (CEA), CGuard™ trends Superior 30 Day DSM ™ i ‘| (Death, Stroke, Myocardial Infarction) * CGuard™ has a superior profile versus historical data on both conventional carotid 6.00% 5.20% 1) stents and s
Slide 16: A Billion Dollar Market Opportunity
m™ A Billion Dollar Market Opportunity Our MicroNet™-covered stents like CGuard™ could become the new gold standard * 2.2M diagnosed with carotid artery disease (CAD) WW carotid procedures today are Carotid procedures tomorrow could be primarily surgical: mostly minimally invasive with Ccuard™ * 201
Slide 17: Commercial Footprint
m= Commercial Footprint (Dark Blue) * Active Selling in 39 Countries * Over 90% of sales are through channel partners / distributors * Short Term Expansion Brazil and France * New countries development include Japan, S Korea and China * IDE Approval progressing with FDA; targeting initiation of US t
Slide 18: Our Lead Product, CGuard - Advancing Rapidly
Mi Our Lead Product, CGuard™ - Advancing Rapidly 31% growth of CGuard™ portfolio in Q4 2019 18,000 Total protected stents sold to date with excellent clinical results CGuard™ has potential to become the new standard-of- care for carotid indications * Achieved clinical milestones; neuroprotective vs
Slide 19: Positioned for Growth
M™ Positioned for Growth MARKET EXPANSION GLOBAL e EXPANSION PRODUCT e EXPANSION INDICATION 4 EXPANSION MARKET CONVERSION e (CEA TO CAS) Penetration SHARE GROWTH IN $ Existing Endo Mkt with' USANDASIA — MicroNet™ Coverage EXISITING CAS MARKET re = \ markets Leverage CGuar _ standard surgical - Lever
Slide 20: Our Advancement Roadmap / Milestones
Our Advancement Roadmap / Milestones Q 2022 and Beyond Expand Broad Global *Launch CGuard™ in U.S. & China Embolic Protection Indications “Advance AV Shunt (Reverse Flow) * Expanded indications for MicroNet™ *Demonstrate Superiority of CGuard™ in CAS *Grow above market in those served *Launch CGuard
Slide 21: Our Robust Intellectual Property Portfolio
M™ Our Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Issued Allowed Pending ¢ InspireMD will continue to USA 14 0 3 strengthen and broaden its patent protection globally to enable future pipeline products Rest of World 33 4 14 inspireMD éontiden
Slide 22: Our Business and Market Development
™ Our Business and Market Development Strategic Targets for Merger or Acquisition Synergy Pe > > CE | = SS Boston, rom ) Medtronic Edwards CardinatHeatth Scientific = Abbott “TERUMO BIOSENSORS “wero COOK’ Weleflex: fil & BMicroror vi cS SILKROAD> ° Steven ne @ \VENUSMEDTECH™ ae @balt @® BIOTRONIK Co
Slide 23: Silk Road - Comparison
m™ Silk Road- Comparison * Ticker SILK * $120 Million IPO ($20 per share) — April 2019 * Valuation at time of IPO — $600 Million * Current Stock Price - $37. 46 * Market Value today - $1.3 Billion * Revenue in 2019 - $63.4 Million (United States Only) Silk Road Stock Performance since IPO _ \ \ aw 4
Slide 24: Capitalization Table
Mi Capitalization Table Capitalization Table ( May 13, 2020) WAEP - $ Face Value$ | Exercise Value$ | % of Fully Diluted Common Shares Outstanding 4,338,910 46.60% Series B Preferred 555,138 $570,999 5.96% Series C Preferred 94,428 $167,971 1.01% Warrants ($1.80-$2.25) i 3,166,665 $1.83 $5,787,497 3
Slide 25: Company Highlights
M™ Company Highlights CGuard™ EPS Benefits Demonstrated in Multiple Trials Commercial Growth $1B Global Market Opportunity Capital Structure Pipeline and Strategic Opportunities Enabling a paradigm shift (CAS) in the treatment of carotid artery disease and stroke prevention Breakthrough platform: Hi
Slide 26: “a = a. wv &
“a 3 = a. wv &